The clinicopathology and surgical outcome of intrahepatic cholangiocarcinomas are not fully understood. The objective of this study was to clarify the clinicopathologic features of intrahepatic cholangiocarcinoma and evaluate prognostic factors influencing survival. Forty consecutive patients with intrahepatic cholangiocarcinomas undergoing surgical resection at Chiba University Hospital between October 1981 and October 1997 were analyzed retrospectively. Intrahepatic cholangiocarcinomas were classified as hilar-invasive type ( n = 26) or peripheral type ( n = 14). Patients with peripheral-type tumors had a significantly ( p = 0.005) better 5-year survival rate (43%) than those with the hilar-invasive type (4%). Hilar-invasive-type tumors had perineural invasion (100%) and nodal involvement (85%) more frequently than did peripheral-type tumors. Despite aggressive surgical resection, the surgical margin was positive in 88% of patients with hilar-invasive type tumors (23/26) and 29% of patients with peripheral-type tumors (4/14). There was no evidence of a survival benefit of vascular resection for patients with a hilar-invasive intrahepatic cholangiocarcinoma. Patients with lymph node metastasis had a significantly worse prognosis ( p = 0.0004). No patients with nodal involvement survived more than 38 months. Negative perineural invasion ( p = 0.008) and a negative microscopic margin ( p = 0.008) were significantly associated with improved survival. Better survival results could be achieved by curative resection with a free margin for hilar-invasive and peripheral intrahepatic cholangiocarcinoma.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00268-002-6696-7DOI Listing

Publication Analysis

Top Keywords

intrahepatic cholangiocarcinoma
16
surgical resection
12
intrahepatic cholangiocarcinomas
12
hilar-invasive type
12
peripheral-type tumors
12
aggressive surgical
8
hilar-invasive peripheral
8
peripheral intrahepatic
8
patients peripheral-type
8
perineural invasion
8

Similar Publications

Fibrolamellar Hepatocellular Carcinoma (FLC) is a rare liver cancer characterized by a fusion oncokinase of the genes DNAJB1 and PRKACA, the catalytic subunit of protein kinase A (PKA). A few FLC-like tumors have been reported showing other alterations involving PKA. To better understand FLC pathogenesis and the relationships among FLC, FLC-like, and other liver tumors, we performed a massive multi-omics analysis.

View Article and Find Full Text PDF

Aldo-keto reductase family 1 member B10 (AKR1B10) is a member of the AKR1B subfamily. It is mainly found in cytoplasm, and it is typically expressed in the stomach and intestines. Given that its expression is low or absent in other tissues, AKR1B10 is a potential diagnostic and therapeutic biomarker for various digestive system diseases.

View Article and Find Full Text PDF

Biomarker potential of plasma cell-free DNA for cholangiocarcinoma.

Heliyon

December 2024

Research Group in Multidimensional Health and Disease (MHD), Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, 12120, Thailand.

Background: To prevent the development of cholangiocarcinoma, an effective screening opisthorchiasis viverrini and/or differential diagnosis of and the cholangiocarcinoma is crucial needed. The level and quality of cfDNA in plasma are being investigated for their potential role as biomarkers in cholangiocarcinoma.

Methods: The study enrolled 43 healthy controls (N), 36 -infected subjects (OV), and 36 cholangiocarcinoma patients (CCA).

View Article and Find Full Text PDF

Evolution of surgical treatment for hepatolithiasis.

World J Gastrointest Surg

December 2024

Department of Hepatobiliary Surgery, The Second People's Hospital of Foshan, Foshan 528000, Guangdong Province, China.

Hepatolithiasis is a common disease where stones are located in the intrahepatic bile duct. Hepatolithiasis is a disease with regional characteristics. The complication and postoperative recurrence rates of the disease are high.

View Article and Find Full Text PDF

Advances in minimally invasive treatment of malignant obstructive jaundice.

World J Gastrointest Surg

December 2024

Department of Outpatient, Puer People's Hospital, Puer 665000, Yunnan Province, China.

Malignant obstructive jaundice (MOJ) encompasses a range of diseases stemming from malignant tumors such as cholangiocarcinoma, pancreatic cancer, and primary liver cancer, among others, which cause obstruction in both intra- and extra-hepatic bile ducts. This obstruction may lead to elevated bilirubin levels, hepatic function impairment, and a low rate of successful surgical resection in clinical settings. There are various minimally invasive treatment options for MOJ, including endoscopic biliary drainage, ultrasound-guided procedures, and percutaneous biliary tract puncture drainage.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!